Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
4.950
-0.110 (-2.17%)
Apr 29, 2026, 9:31 AM EDT - Market open
Protara Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -57.44 | -44.6 | -40.42 | -65.95 | -47.25 | |
| Depreciation & Amortization | 0.36 | 0.33 | 0.34 | 0.25 | 0.12 | |
| Asset Writedown & Restructuring Costs | - | - | - | 29.52 | - | |
| Loss (Gain) From Sale of Investments | -1.25 | -0.69 | -0.44 | 1.14 | 1.74 | |
| Stock-Based Compensation | 3.83 | 4.13 | 6.09 | 6.69 | 10.36 | |
| Other Operating Activities | 1.08 | 1.01 | 1.01 | 1.37 | 1.05 | |
| Change in Accounts Payable | -0.87 | 1.38 | 0.85 | 0.63 | 0.04 | |
| Change in Other Net Operating Assets | -2.07 | 2.63 | -4.99 | -0.09 | -0.56 | |
| Operating Cash Flow | -56.37 | -35.81 | -37.56 | -26.46 | -34.5 | |
| Capital Expenditures | -0.09 | -0.06 | -0.05 | -0.12 | -0.6 | |
| Investment in Securities | -139.4 | 19.22 | 53.15 | 15.07 | -97.6 | |
| Investing Cash Flow | -139.49 | 19.16 | 53.11 | 14.95 | -98.19 | |
| Issuance of Common Stock | 83.73 | 149.03 | - | - | - | |
| Repurchase of Common Stock | -0.19 | -0.08 | -0.09 | -0.09 | -0.23 | |
| Other Financing Activities | -0.83 | -9.09 | - | - | - | |
| Financing Cash Flow | 82.72 | 139.87 | -0.09 | -0.09 | -0.23 | |
| Net Cash Flow | -113.14 | 123.21 | 15.46 | -11.6 | -132.92 | |
| Free Cash Flow | -56.46 | -35.87 | -37.6 | -26.58 | -35.1 | |
| Free Cash Flow Per Share | -1.32 | -1.74 | -3.32 | -2.36 | -3.13 | |
| Levered Free Cash Flow | -38.48 | -20.39 | -21.88 | -15.16 | -20.23 | |
| Unlevered Free Cash Flow | -38.48 | -20.39 | -21.88 | -15.16 | -20.23 | |
| Change in Working Capital | -2.94 | 4.01 | -4.14 | 0.54 | -0.52 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.